Compare · LEXX vs NVO
LEXX vs NVO
Side-by-side comparison of Lexaria Bioscience Corp. (LEXX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LEXX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $192.84B, about 14401.9x LEXX ($13.4M).
- Over the past year, LEXX is down 42.0% and NVO is down 41.5% - NVO leads by 0.6 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for LEXX).
- NVO has more recent analyst coverage (25 ratings vs 0 for LEXX).
- Company
- Lexaria Bioscience Corp.
- Novo Nordisk A/S
- Price
- $0.59-2.84%
- $43.19-0.75%
- Market cap
- $13.4M
- $192.84B
- 1M return
- +0.88%
- -2.46%
- 1Y return
- -42.04%
- -41.47%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 3
- 4
- Recent ratings
- 0
- 25
Lexaria Bioscience Corp.
Lexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest LEXX
- GLP-1 'Arms Race' Intensifies as the Addressable Markets Continue to Expand
- Lexaria's Animal Study Examining Next-Generation GLP-1 drugs is Underway
- Lexaria Attending the BIO International Convention, as Part of a Broader Business Development Program
- Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
- Lexaria Bioscience Releases Second Episode of Investor Video Series
- Lexaria Updates Progress on Human Study #7
- Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
- Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
- Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
- Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S